Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Arielle Redfern"'
Autor:
Rima Patel, Zhiqiang Li, Brittney S. Zimmerman, Marc Y. Fink, Jason D. Wells, Xiang Zhou, Kristin L. Ayers, Arielle Redfern, Scott Newman, Rong Chen, William K. Oh, Amy Tiersten
Publikováno v:
Cancer Research. 82:P1-17
Background: Aromatase inhibitors (AIs) are part of standard endocrine therapy for hormone receptor (HR)-positive breast cancer (BC) and are used in both adjuvant and metastatic settings. Since AIs work by inhibiting the conversion of androgens to est
Autor:
Rima Patel, Zhiqiang Li, Brittney S. Zimmerman, Marc Y. Fink, Jason D. Wells, Xiang Zhou, Kristin Ayers, Arielle Redfern, Scott Newman, Eric Schadt, William K. Oh, Rong Chen, Amy Tiersten
Publikováno v:
Breast Cancer Research and Treatment. 192:313-319
Higher levels of estrogen in obese patients may lead to incomplete inhibition by aromatase inhibitors (AIs). The aim of this study was to determine the impact of body mass index (BMI) on efficacy of AIs in patients with metastatic hormone receptor (H
Autor:
Whitney Jappe, Juan P. Wisnivesky, Eric E. Schadt, Tommy Mullaney, Tony Prentice, Scott B. Jones, Meng Ma, Xiang Zhou, Kristin L. Ayers, Rajwanth R. Veluswamy, Kyeryoung Lee, Fred R. Hirsch, Shuyu D. Li, Michelle Zimmerman, Howard Goldsweig, Li Li, Jane J. Liu, Scott Newman, Rong Chen, Arielle Redfern, Zongzhi Liu, Nicholas Hahner, Kamlesh K Yadav, William Oh, Matthew Dietz
Publikováno v:
The Oncologist
Background Racial disparities among clinical trial participants present a challenge to assess whether trial results can be generalized into patients representing diverse races and ethnicities. The objective of this study was to evaluate the impact of
Autor:
Paul McDonagh, Tony Prentice, Minghao Li, Christopher Gilman, Arielle Redfern, Zongzhi Liu, Meng Ma, Yun Mai, Eric E. Schadt, Kyeryoung Lee, Qi Pan, Tommy Mullaney, Rong Chen, Mingwei Zhang, Xiaoyan Wang
Publikováno v:
Journal of Clinical Oncology. 39:e18747-e18747
e18747 Background: Accurate longitudinal cancer treatments are vital for establishing primary endpoints such as outcome as well as for the investigation of adverse events. However, many longitudinal therapeutic regimens are not well captured in struc
Autor:
Y. Li, Philip C. Mack, Marc Y. Fink, Tony Prentice, Kristin L. Ayers, Eric E. Schadt, Fred R. Hirsch, Scott Newman, Tommy Mullaney, Timmy O’Connell, Sunny Guin, W. Jappe, Z. Li, Michael I. Klein, Rong Chen, Y. Gong, Arielle Redfern, X. Zhou
Publikováno v:
Journal of Thoracic Oncology. 16:S423
Autor:
Dan Li, Rong Chen, Zongzhi Liu, Tony Prentice, Scott B. Jones, Xiaoyan Wang, Kyeryoung Lee, Christopher Gilman, Eric E. Schadt, Arielle Redfern, Tommy Mullaney, Yun Mai, Matthew Deitz, Xiang Zhou, Ying Ru, Meng Ma, Yunrou Gong
Publikováno v:
Journal of Clinical Oncology. 38:e14062-e14062
e14062 Background: Real world evidence generated from electronic health records (EHRs) is playing an increasing role in health care decisions. It has been recognized as an essential element to assess cancer outcomes in real-world settings. Automatica
Autor:
Scott Newman, Kyeryoung Lee, Li Li, Eric E. Schadt, Tommy Mullaney, Xiang Zhou, Rong Chen, Dan Li, Kristin L. Ayers, Whitney Jappe, Arielle Redfern, Michelle Zimmerman, William Oh, Zongzhi Liu, Meng Ma, Tony Prentice
Publikováno v:
Journal of Clinical Oncology. 38:e21514-e21514
e21514 Background: Although some advanced non-small cell lung cancer (aNSCLC) patients respond favorably to immune checkpoint inhibitors, a larger portion either do not respond or experience negative side effects. At present, there is no consensus on
Autor:
Qi Pan, Kamlesh K Yadav, Kartikey Grover, Dan Li, Rong Chen, William Oh, Arielle Redfern, Tony Prentice, Howard Goldsweig, Whitney Jappe, Zongzhi Liu, Michelle Zimmerman, Xiang Zhou, Li Li, Meng Ma, Eric E. Schadt, Tommy Mullaney
Publikováno v:
Journal of Clinical Oncology. 37:e18141-e18141
e18141 Background: Clinical trials remain the most reliable means to evaluate drug efficacy and safety for evidence-based cancer care. However, there is a significant racial disparity among participants in clinical trials. For example, only 1-3% of t
Autor:
Tony Prentice, Whitney Jappe, Marc Y. Fink, Michelle Zimmerman, Qi Pan, Howard Goldsweig, Eric E. Schadt, Tommy Mullaney, Arielle Redfern, Dan Li, Rong Chen, Zhiqiang Li, Kartikey Grover, Li Li, Xiang Zhou, Jonathan McCafferty, William Oh, Meng Ma
Publikováno v:
Journal of Clinical Oncology. 37:e18031-e18031
e18031 Background: Off-label drug use is common in cancer treatment (tx) due to limited approved tx options. Systematic analysis of RWD for off-label drug use facilitates hypothesis generation and design of clinical studies for new indications. Metho
Autor:
Scott Jones, Rong Chen, Qi Pan, Xiang Zhou, Dan Li, Zongzhi Liu, Whitney Jappe, Eric E. Schadt, Tommy Mullaney, William Oh, Matthew Dietz, Dianwei Han, Nicholas Hahner, Michelle Zimmerman, Howard Goldsweig, Fred R. Hirsch, Meng Ma, Kamlesh K Yadav, Arielle Redfern, Tony Prentice
Publikováno v:
Journal of Clinical Oncology. 37:e20642-e20642
e20642 Background: While optimal sequencing of systemic therapy in aNSCLC is critical to achieve maximal clinical benefit, it is practically challenging to study tx sequencing through clinical trials. RWD allow retrospective, observational studies to